INOVIO is committed to developing new, innovative therapies to fight HPV-related diseases, cancer and infectious diseases. Our goal is to deliver on the promise of DNA medicines for patients around the globe.
INOVIO currently has the following clinical trials enrolling. For more information please email clinical.trials@inovio.com.
| Disease | Program | Study Phase | Summary |
|---|---|---|---|
| DiseaseBRCA1/2 Mutation Carriers (More Information) |
ProgramINO-5401 | Study PhasePhase 1 | SummaryThe research study is being conducted to test an experimental vaccine to potentially prevent cancer for people with BRCA1 or BRCA2 mutations. This study will test if the vaccine is safe (without significant side effects) and test a new way of administering vaccines. It will also test whether the vaccine activates your immune system. |
| DiseaseHIV-Positive Anal High-Grade Squamous Intraepithelial Lesions (HSIL) (More Information) |
ProgramVGX-3100 | Study PhasePhase 2 | SummaryThis Phase 2 trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 and electroporation in treating patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Electroporation helps pores in your body's cells take in the drug to strengthen your immune system's response. Giving VGX-3100 and electroporation together may work better in treating patients with high-grade anal lesions. |
| DiseasedMAb (More Information) |
ProgramdMAb-1 and dMAb-2 | Study PhasePhase 1 | SummaryThis is a Phase 1, open-label, single center, dose escalation study to evaluate the safety and pharmacokinetic profile of mAb-1 and mAb-2 following delivery of optimized dMAb-1 and dMAb-2 with Hylenex® recombinant, administered by intramuscular injection (IM) followed immediately by electroporation (EP) device, in a 2-dose regimen (Days 0 and 3) in healthy adults. The hypothesis is that the administration of dMAb-1 and dMAb-2 will be safe and associated with expression of mAb-1 and mAb-2 in serum. |
SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases
© Copyright 2024 INOVIO Pharmaceuticals. All rights reserved.
